Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EOLS
CUSIPN/A
Phone949-284-4555
Debt
Debt-to-Equity RatioN/A
Current Ratio13.84
Quick Ratio13.84
Price-To-Earnings
Trailing P/E Ratio-82.70
Forward P/E Ratio-13.53
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees21
Outstanding Shares23,640,000
Market Cap$618.66
Evolus (NASDAQ:EOLS) Frequently Asked Questions
What is Evolus' stock symbol?
Evolus trades on the NASDAQ under the ticker symbol "EOLS."
How were Evolus' earnings last quarter?
Evolus Inc (NASDAQ:EOLS) announced its quarterly earnings data on Thursday, May, 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.06. View Evolus' Earnings History.
What price target have analysts set for EOLS?
4 brokerages have issued twelve-month target prices for Evolus' stock. Their forecasts range from $24.00 to $35.00. On average, they expect Evolus' stock price to reach $30.50 in the next twelve months. This suggests a possible upside of 36.6% from the stock's current price. View Analyst Ratings for Evolus.
What is the consensus analysts' recommendation for Evolus?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Evolus stock?
Here are some recent quotes from research analysts about Evolus stock:
- 1. According to Zacks Investment Research, "Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. " (7/17/2018)
- 2. Cantor Fitzgerald analysts commented, ". We are raising our 12-month PT for EOLS shares to $35 from $25. The increase in our PT is driven by multiple expansion now that visibility has improved for the peak sales potential of DWP-450 (new CEO from AGN (Neutral), new CFO from RVNC (OW), expansion of commercial team and completion of response to CRL this summer). We use a blend of DCF and EV/ EBITDA analysis to arrive at our new $35 PT." (6/7/2018)
- 3. Mizuho analysts commented, "We lowered our estimates and pushed out the forecast (U.S. launch in 3Q:19 vs. 1Q:19 previously), driving a PT reduction to $16 from $21. Reiterate Buy." (5/16/2018)
Who are some of Evolus' key competitors?
Some companies that are related to Evolus include TESARO (TSRO), Spectrum Pharmaceuticals (SPPI), Akcea Therapeutics (AKCA), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Myokardia (MYOK), Prestige Brands (PBH), Phibro Animal Health (PAHC) and Insmed (INSM).
Who are Evolus' key executives?
Evolus' management team includes the folowing people:
- Dr. Rui Avelar M.D., Chief Medical Officer (Age 56)
- Mr. David Moatazedi, Pres & CEO (Age 40)
- Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 59)
- Dr. J. Christopher Marmo Ph.D., Chief Operating Officer (Age 49)
- Jeffrey J. Plumer, VP of Legal
When did Evolus IPO?
(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.
When does Evolus' lock-up period expire?
Evolus' lock-up period expires on Tuesday, August 7th. Evolus had issued 5,000,000 shares in its public offering on February 8th. The total size of the offering was $60,000,000 based on an initial share price of $12.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.
Has Evolus been receiving favorable news coverage?
News articles about EOLS stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Evolus earned a daily sentiment score of 0.17 on Accern's scale. They also gave press coverage about the company an impact score of 47.56 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Evolus' major shareholders?
Evolus' stock is owned by many different of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.08%). Company insiders that own Evolus stock include Bosun Hau, Kristine Romine and Vikram Malik. View Institutional Ownership Trends for Evolus.
Which institutional investors are buying Evolus stock?
EOLS stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have bought Evolus stock in the last two years include Bosun Hau, Kristine Romine and Vikram Malik. View Insider Buying and Selling for Evolus.
How do I buy shares of Evolus?
Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Evolus' stock price today?
One share of EOLS stock can currently be purchased for approximately $22.33.
How big of a company is Evolus?
Evolus has a market capitalization of $618.66 million. The company earns $-4,480,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Evolus employs 21 workers across the globe.
How can I contact Evolus?
Evolus' mailing address is 17901 Von Karman Avenue Suite 150, Irvine CA, 92614. The company can be reached via phone at 949-284-4555 or via email at [email protected]
MarketBeat Community Rating for Evolus (NASDAQ EOLS)
MarketBeat's community ratings are surveys of what our community members think about Evolus and other stocks. Vote "Outperform" if you believe EOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EOLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
